The DOI matches its Crossref record; 31 of the 34 references it cites were found in a registry or an index.
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Abstract
Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib. However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain.Methods We did an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centres in Japan. 177 chemotherapy-naive patients aged 75 years or younger and diagnosed with stage IIIB/IV non-small-cell lung cancer or postoperative recurrence harbouring EGFR mutations (either the exon 19 deletion or L858R point mutation) were randomly assigned, using a minimisation technique, to receive either gefitinib (250 mg/day orally; n=88) or cisplatin (80 mg/m(2), intravenously) plus docetaxel (60 mg/m(2), intravenously; n=89), administered every 21 days for three to six cycles. The primary endpoint was progression-free survival. Survival analysis was done with the modified intention-to-treat population. This study is registered with UMIN (University Hospital Medical Information Network in Japan), number 000000539.Findings Five patients were excluded (two patients were found to have thyroid and colon cancer after randomisation, one patient had an exon 18 mutation, one patient had insufficient consent, and one patient showed acute allergic reaction to docetaxel). Thus, 172 patients (86 in each group) were included in the survival analyses. The gefitinib group had significantly longer progression-free survival compared with the cisplatin plus docetaxel goup, with a median progression-free survival time of 9.2 months (95% CI 8.0-13.9) versus 6.3 months (5.8-7.8; HR 0.489, 95% CI 0.336-0.710, log-rank p<0.0001). Myelosuppression, alopecia, and fatigue were more frequent in the cisplatin plus docetaxel group, but skin toxicity, liver dysfunction, and diarrhoea were more frequent in the gefitinib group. Two patients in the gefitinib group developed interstitial lung disease (incidence 2.3%), one of whom died.Interpretation Patients with lung cancer who are selected by EGFR mutations have longer progression-free survival if they are treated with gefitinib than if they are treated with cisplatin plus docetaxel.Funding West Japan Oncology Group (WJOG): a non-profit organisation supported by unrestricted donations from several pharmaceutical companies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“have shown improved efficacy and tolerability compared with chemotherapy in numerous phase III trials”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [30]
In the citing paper
“In clinical trials, the incidence of all-grade liver injury due to different smallmolecule targeted drugs such as tyrosine kinase inhibitors is reportedly 5-55% [144-149].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [145]
In the citing paper
“Eight randomised controlled phase III trials (table 1) have demonstrated that first-generation or second-generation EGFR-TKIs represent the best first-line treatment option in patients with advanced NSCLC whose tumours harbour EGFR mutations, when compared with chemotherapy, because they significantly improved the RR and progression-free survival (PFS).4–11”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [5]
In the citing paper
“Unfortunately, whilst patients with EGFRm+ tumors typically show good initial responses to first generation TKIs, most patients who respond to therapy ultimately develop disease progression after about 9-14 months of treatment (7-11).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [8]
In the citing paper
“Most patients whose tumors harbor exon 19 deletions or L858R EGFR activating mutations have radiographic responses to monotherapy with the reversible adenosine triphosphate (ATP)-competitive EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib 17–23 and the irreversible EGFR TKI afatinib 24.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [21]
In the citing paper
“Several randomized clinical trials have demonstrated that EGFR TKIs are more effective, as measured by response rate (RR) and progression free survival (PFS), than chemotherapy when used as initial systemic treatment for advanced EGFR mutant NSCLC (1, 4–9).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [9]
In the citing paper
“Several other trials conducted in Asia confirmed the superiority of Gefitinib over chemotherapy in EGFR-mutated patients [16, 44, 64].”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [16]
In the citing paper
“Targeted therapies for these lung cancers were established based on 7 phase III randomized trials.5, 6, 7, 8, 9, 10, 11”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [6]
In the citing paper
“Randomized phase III trials have demonstrated the superiority of these TKI, in terms of progression free survival (PFS), to conventional chemotherapy in patients with lung cancers harboring EGFR mutations.5, 6, 11”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [6]
In the citing paper
“Evidence of these common mutations has been developed in prospective trials: gefitinib, erlotinib and afatinib showed ORR of approximately 60% and PFS of 9–13 months.5, 6, 7, 8, 9, 10, 11”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [6]
In the citing paper
“Despite high tumor response rates with first-line EGFR-TKIs, disease progresses in a majority of patients after 9 to 13 months of treatment.5–12”
From Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2017) · cites this paper as [6]
In the citing paper
“Several studies have consistently demonstrated that the EGFR TKIs (gefitinib, erlotinib and afatinib) produce higher RRs, longer PFS and improve QoL compared with standard platinum-based doublet chemotherapy in patients with good PS (PS 0-2), whose tumour harbours an activating (sensitising) EGFR mutation [105-112].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [109]
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationComparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Self-citationKris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802714 · Cited by 2,435
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Research works printed but not linked: 2
- Cappuzzo, 2009, Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study, J Thorac Oncol, 4
- Lee, 2009, A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung, J Thorac Oncol, 4
Cited by
Sorted by citations
Items 301–400 of 1,010
Goldberg, S. B., Oxnard, G. R., Digumarthy, S., Muzikansky, A., Jackman, D. M., Lennes, I. T., & Sequist, L. V. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0168 · Cited by 130
The Evolution of Therapies in Non-Small Cell Lung Cancer
Boolell, V., Alamgeer, M., Watkins, D. N., & Ganju, V. (2015) · Cancers · doi:10.3390/cancers7030864 · Cited by 130
Kosaka, T., Yamaki, E., Mogi, A., & Kuwano, H. (2011) · BioMed Research International · doi:10.1155/2011/165214 · Cited by 130
Wang, Z., Chen, R., Wang, S., Zhong, J., Wu, M., Zhao, J., Duan, J., Zhuo, M., An, T., Wang, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110780 · Cited by 130
Lee, J. J.-K., Shin, J. Y., Kim, S., Lee, S., Park, C. C., Kim, J. Y., Koh, Y., Keam, B., Min, H. S., Kim, T. M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt127 · Cited by 130
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 131
EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
Karachaliou, N., Fernández-Bruno, M., Bracht, J. W. P., & Rosell, R. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.06 · Cited by 131
Matsubara, E., Yano, H., Pan, C., Komohara, Y., Fujiwara, Y., Zhao, S., Shinchi, Y., Kurotaki, D., & Suzuki, M. (2023) · Cancers · doi:10.3390/cancers15082250 · Cited by 130
Rai, K., Takigawa, N., Ito, S., Kashihara, H., Ichihara, E., Yasuda, T., Shimizu, K., Tanimoto, M., & Kiura, K. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0220 · Cited by 129
Skin problems and EGFR-tyrosine kinase inhibitor
Kozuki, T. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv207 · Cited by 129
Jänne, P. A., Ou, S.-H. I., Kim, D.-W., Oxnard, G. R., Martins, R., Kris, M. G., Dunphy, F., Nishio, M., O'Connell, J., Paweletz, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70461-9 · Cited by 127
Reungwetwattana, T., Weroha, S. J., & Molina, J. R. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.09.004 · Cited by 127
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
Jorge, S. E., Kobayashi, S. S., & Costa, D. B. (2014) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20144099 · Cited by 127
Role of epidermal growth factor receptor in lung cancer and targeted therapies.
Liu, T., Jin, X., Wang, Y., & Wang, K. (2017) · Europe PMC (PubMed Central) · Cited by 131
Hensing, T. A., Chawla, A., Batra, R., & Salgia, R. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-8778-4_5 · Cited by 127
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
Juchum, M., Günther, M., & Laufer, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.002 · Cited by 126
Wu, X., Wu, Y., Ye, H., Yu, S., He, C., & Chen, X. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.011 · Cited by 126
Adenosquamous carcinoma of the lung
Li, C., & Lu, H. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s164574 · Cited by 125
The impact of the Cancer Genome Atlas on lung cancer
Chang, J. T.-H., Lee, Y. M., & Huang, R. S. (2015) · Translational research · doi:10.1016/j.trsl.2015.08.001 · Cited by 125
Yoshida, T., Ishii, G., Goto, K., Neri, S., Hashimoto, H., Yoh, K., Niho, S., Umemura, S., Matsumoto, S., Ohmatsu, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0846 · Cited by 125
Janjigian, Y. Y., Azzoli, C. G., Krug, L. M., Pereira, L. K., Rizvi, N. A., Pietanza, M. C., Kris, M. G., Ginsberg, M. S., Pao, W. J., Miller, V. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2662 · Cited by 124
Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey
Gregg, J. P., Li, T., & Yoneda, K. Y. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.14 · Cited by 124
Lee, V. H.-F., Tin, V. P., Choy, T., Lam, K. O., Choi, C., Chung, L.-P., Tsang, J. W. H., Ho, P., Leung, D. K., Ma, E. S. K., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829f684a · Cited by 123
Optimizing Endobronchial Ultrasound for Molecular Analysis. How Many Passes Are Needed?
Yarmus, L. B., Akulian, J., Gilbert, C. R., Feller-Kopman, D. J., Lee, H. J., Zarogoulidis, P., Lechtzin, N., Ali, S. Z., & Sathiyamoorthy, V. (2013) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201305-130oc · Cited by 123
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
Wang, Y., Schmid‐Bindert, G., & Zhou, C. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011427927 · Cited by 124
An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma
Li, X., Shi, Y., Yin, Z., Xue, X., & Zhou, B. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-159 · Cited by 123
Westwood, M. E., Joore, M. A., Whiting, P. F., van Asselt, A. D. I., Ramaekers, B. L. T., Armstrong, N., Misso, K., Severens, J. L., & Kleijnen, J. (2014) · Health Technology Assessment · doi:10.3310/hta18320 · Cited by 123
Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012
Hirsch, F. R., Janne, P. A., Eberhardt, W., Cappuzzo, F., Thatcher, N., Pirker, R., Choy, H., Kim, E. S., Paz-Ares, L. G., Gandara, D. R., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827ed0ff · Cited by 122
Self-citationTargeted therapy for non-small-cell lung cancer: past, present and future
Forde, P. M., & Ettinger, D. S. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.47 · Cited by 123
Chen, G., Feng, J., Zhou, C., Wu, Y.-L., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt012 · Cited by 121
Roengvoraphoj, M., Tsongalis, G. J., Dragnev, K. H., & Rigas, J. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.001 · Cited by 121
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
Agulnik, M., Nelson, Ziehr, & Johnson, J. R. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s23165 · Cited by 121
Mazières, J., Brugger, W., Cappuzzo, F., Middel, P., Frosch, A., Bāra, I., Klingelschmitt, G., & Klughammer, B. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.016 · Cited by 122
Bahce, I., Smit, E. F., Lubberink, M., van der Veldt, A. A. M., Yaqub, M. M., Windhorst, A. D., Schuit, R. C., Thunnissen, E., Heideman, D. A. M., Postmus, P. E., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0289 · Cited by 120
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
Shaw, A. T., Varghese, A. M., Solomon, B., Costa, D. B., Novello, S., Mino-Kenudson, M. A., Awad, M. M., Engelman, J. A., Riely, G. J., Monica, V., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds242 · Cited by 120
Kohsaka, S., Petronczki, M. P., Solca, F., & Maemondo, M. (2018) · Future Oncology · doi:10.2217/fon-2018-0736 · Cited by 123
Tong, L., Ding, N., Tong, X., Li, J., Zhang, Y., Wang, X., Xu, X., Ye, M., Li, C., Wu, X., et al. (2019) · Theranostics · doi:10.7150/thno.34070 · Cited by 120
Zhao, H., Yao, W., Min, X., Gu, K., Yu, G., Zhang, Z., Cui, J., Miao, L., Zhang, L., Yuan, X., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.006 · Cited by 123
Fujita, Y., Suda, K., Kimura, H., Matsumoto, K., Arao, T., Nagai, T., Saijo, N., Yatabe, Y., Mitsudomi, T., & Nishio, K. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182653d7f · Cited by 119
Self-citationYamada, T., Takeuchi, S., Nakade, J., Kita, K., Nakagawa, T., Nanjo, S., Nakamura, T., Matsumoto, K., Soda, M., Mano, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2972 · Cited by 119
Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy
Chalela, R., Curull, V., Enríquez-Rodríguez, C. J., Pijuán, L., Bellosillo, B., & Gea, J. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.06.20 · Cited by 119
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009619666181210114559 · Cited by 120
Pilkington, G., Boland, A., Brown, T. J., Oyee, J., Bagust, A., & Dickson, R. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-205914 · Cited by 118
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights
Meador, C. B., & Hata, A. N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107522 · Cited by 119
König, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 119
Nakajima, T., Yasufuku, K., Nakagawara, A., Kimura, H., & Yoshino, I. (2011) · CHEST Journal · doi:10.1378/chest.10-3186 · Cited by 117
Sullivan, I., & Planchard, D. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2016.00076 · Cited by 119
Moghadamtousi, S. Z., Kadir, H. A., Paydar, M., Rouhollahi, E., & Karimian, H. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-299 · Cited by 117
Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer
Shen, H., Zhu, F., Liu, J., Xu, T., Pei, D., Wang, R., Qian, Y., Li, Q., Wang, L., Shi, Z., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103305 · Cited by 116
Gadgeel, S. M., & Wozniak, A. J. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.12.001 · Cited by 116
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220931926 · Cited by 115
Li, Y., Li, Y., Yang, T., Wei, S., Wang, J., Wang, M., Wang, Y., Zhou, Q., Liu, H., & Chen, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052093 · Cited by 115
Dong, J., Li, B., Lin, D. C.-C., Zhou, Q., & Huang, D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00230 · Cited by 115
Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury
Ohmori, T., Yamaoka, T., Andō, K., Kusumoto, S., Kishino, Y., Manabe, R., & Sagara, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020792 · Cited by 116
50 Years of Progress in the Systemic Therapy of Non–Small Cell Lung Cancer
Wakelee, H. A., Kelly, K. L., & Edelman, M. J. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.177 · Cited by 114
Shi, L., Tang, J., Li, T., & Liu, Z. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.016 · Cited by 115
Incidence and consequences of bone metastases in lung cancer patients
Kuchuk, M., Addison, C., Clemons, M. J., Kuchuk, I., & Wheatley‐Price, P. (2013) · Journal of bone oncology · doi:10.1016/j.jbo.2012.12.004 · Cited by 114
Keam, B., Kim, D.-W., Park, J. H., Lee, J.-O., Kim, T. M., Lee, S.-H., Chung, D. H., & Heo, D. S. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-013-0602-1 · Cited by 113
Karampeazis, A., Voutsina, A., Souglakos, J., Kentepozidis, N., Giassas, S., Christofillakis, C., Kotsakis, A., Papakotoulas, P., Rapti, A., Agelidou, M., et al. (2013) · Cancer · doi:10.1002/cncr.28132 · Cited by 113
Menis, J., Hasan, B., & Besse, B. (2014) · European Respiratory Review · doi:10.1183/09059180.00004214 · Cited by 113
Gao, J., Li, H.-R., Jin, C., Jiang, J., & Ding, J. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02075-1 · Cited by 113
Nomogram to predict the presence ofEGFRactivating mutation in lung adenocarcinoma
Girard, N., Sima, C. S., Jackman, D. M., Sequist, L. V. D., Chen, H., Yang, J. C., Ji, H., Waltman, B. A., Rosell, R., Tarón, M., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00010111 · Cited by 113
Preparation of DNA from cytological material
Dejmek, A., Zendehrokh, N., Tomaszewska, M., & Edsjö, A. (2013) · Cancer Cytopathology · doi:10.1002/cncy.21276 · Cited by 112
Stewart, E., Mascaux, C., Pham, N., Sakashita, S., Sykes, J. R., Kim, L., Yanagawa, N., Allo, G., Ishizawa, K., Wang, D. Y. Q., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1492 · Cited by 112
Wu, Y., Chang, I., Wang, C.-L., Chen, T., Chen, Y., Liu, H., Chu, Y., Chiu, Y.-T., Wu, T., Chou, L.-H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070839 · Cited by 111
Donev, I. S., Wang, W., Yamada, T., Li, Q., Takeuchi, S., Matsumoto, K., Yamori, T., Nishioka, Y., Sone, S., & Yano, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1993 · Cited by 111
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Perez‐Gracia, J. L., Sanmamed, M. F., Bosch, A., Patiño‐García, A., Schalper, K. A., Segura, V., Joaquim Bellmunt, B., Tabernero, J. M., Sweeney, C. J., Choueiri, T. K., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.005 · Cited by 112
EGFR G796D mutation mediates resistance to osimertinib
Zheng, D., Hu, M., Bai, Y., Zhu, X., Lu, X., Wu, C., Wang, J., Liu, L., Wang, Z., Ni, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17913 · Cited by 111
Xiong, L., Li, R., Sun, J., Lou, Y., Zhang, W., Bai, H., Wang, H., Shen, J., Jing, B., Shi, C., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0120 · Cited by 111
Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110
Kobayashi, K., & Hagiwara, K. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0258-9 · Cited by 110
Sugawara, S., Oizumi, S., Minato, K., Harada, T., Inoue, A., Fujita, Y., Maemondo, M., Yoshizawa, H., Ito, K., Gemma, A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv063 · Cited by 110
Self-citationBria, E., Milella, M., Cuppone, F., Novello, S., Ceribelli, A., Vaccaro, V., Sperduti, I., Gelibter, A. J., Scagliotti, G. V., Cognetti, F., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq742 · Cited by 110
Yamada, T., Hirai, S., Katayama, Y., Yoshimura, A., Shiotsu, S., Watanabe, S., Kikuchi, T., Hirose, K., Kubota, Y., Chihara, Y., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2037 · Cited by 110
Treatment of Non-small Cell Lung Cancer with EGFR-mutations
Yoneda, K., Imanishi, N., Ichiki, Y., & Tanaka, F. (2019) · Journal of UOEH · doi:10.7888/juoeh.41.153 · Cited by 111
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
O’Leary, C. G., Gasper, H. M., Sahin, K. B., Tang, M., Kulasinghe, A., Adams, M. N., Richard, D. J., & O'Byrne, K. J. (2020) · Pharmaceuticals · doi:10.3390/ph13100273 · Cited by 114
Clinical application of amplicon-based next-generation sequencing in cancer
Chang, F., & Li, M. M. (2013) · Cancer Genetics · doi:10.1016/j.cancergen.2013.10.003 · Cited by 109
Jing, N., Du, Y., Chen, X., Bai, Q., Wang, Y., Zhang, X., Zhu, N., Zhang, J., Hou, J., Wang, Q. L., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0464 · Cited by 109
The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies
Greulich, H. E. (2010) · Genes & Cancer · doi:10.1177/1947601911407324 · Cited by 109
Targeting EGFR in Lung Cancer: Current Standards and Developments
Díaz-Serrano, A., Gella, P., Jiménez, E., Zugazagoitia, J., & Paz-Ares Rodríguez, L. (2018) · Drugs · doi:10.1007/s40265-018-0916-4 · Cited by 108
Kato, T., Yoshioka, H., Okamoto, I., Yokoyama, A., Hida, T., Seto, T., Kiura, K., Massey, D., Seki, Y., & Yamamoto, N. (2015) · Cancer Science · doi:10.1111/cas.12723 · Cited by 108
Self-citationAzuma, K., Kawahara, A., Sonoda, K., Nakashima, K., Tashiro, K., Watari, K., Izumi, H., Kage, M., Kuwano, M., Ono, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1866 · Cited by 108
Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors
Amrhein, J. A., Knapp, S., & Hanke, T. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00217 · Cited by 108
An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma
Rodriguez, S. M. B., Kamel, A. E., Ciubotaru, G. V., Onose, G., Sevastre, A.-S., Sfredel, V., Dănoiu, S., Dricu, A., & Tătăranu, L. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311110 · Cited by 108
Lung cancer: Prevalent trends & emerging concepts
Raina, V., & Malik, P. S. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.154479 · Cited by 109
Lung cancer in never smokers: Change of a mindset in the molecular era
Lee, Y. J., Kim, J.-H., Kim, S. I., Ha, S., Mok, T. S. K., Mitsudomi, T., & Cho, B. C. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.12.013 · Cited by 107
Self-citationManagement of co-existent tuberculosis and lung cancer
Ho, J., & Leung, C. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.05.030 · Cited by 107
Brown, B. P., Zhang, Y., Westover, D., Yan, Y., Qiao, H., Huang, V., Du, Z., Smith, J. A., Ross, J. S., Miller, V. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3829 · Cited by 107
Reita, D., Pabst, L., Pencreach, E., Guérin, É., Dano, L., Rimelen, V., Voegeli, A., Vallat, L. D., Mascaux, C., & Beau‐Faller, M. (2021) · Cancers · doi:10.3390/cancers13194926 · Cited by 107
Dai, J., Qu, T., Yin, D., Cui, Y., Zhang, C., Zhang, E., & Guo, R. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05840-x · Cited by 107
Chung, H. W., Lee, K. Y., Kim, H. J., Kim, W. S., & So, Y. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1545-7 · Cited by 107
Targeted next‐generation sequencing using fine‐needle aspirates from adenocarcinomas of the lung
Karnes, H. E., Duncavage, E. J., & Bernadt, C. T. (2013) · Cancer Cytopathology · doi:10.1002/cncy.21361 · Cited by 106
Nakajima, T., & Yasufuku, K. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318200f496 · Cited by 106
Yoshida, T., Zhang, G., Smith, M. A., Lopez, A. S., Bai, Y., Li, J., Fang, B., Koomen, J. M., Rawal, B., Fisher, K. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1559 · Cited by 106
Self-citationTwo plasma microRNA panels for diagnosis and subtype discrimination of lung cancer
Lu, S., Kong, H., Hou, Y., Ge, D., Huang, W., Ou, J., Yang, D., Zhang, L., Wu, G., Song, Y., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.027 · Cited by 106
Araki, T., Kanda, S., Horinouchi, H., & Ohe, Y. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad052 · Cited by 106
Li, N., Ou, W., Xiong, Y., Sun, H.-B., Zhang, L., Fang, Q., Zhang, S.-L., Wang, B.-X., & Wang, S. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3586-9 · Cited by 106
Targeted Therapies for Lung Cancer
Larsen, J. E., Cascone, T., Gerber, D. E., Heymach, J. V., & Minna, J. D. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e701a · Cited by 106
Ichihara, E., Hotta, K., Nogami, N., Kuyama, S., Kishino, D., Fujii, M., Kozuki, T., Tabata, M., Harada, D., Chikamori, K., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000434 · Cited by 105
Hsu, K.-H., Huang, Y.-H., Tseng, J., Chen, K., Ku, W., Su, K., Chen, J. J. W., Chen, H., Yu, S., Yang, T., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.021 · Cited by 105
Metadata
- Authors
- Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K., & Fukuoka, M.
- Affiliations
- Aichi Cancer Center (JP)
- Yokohama City University Medical Center (JP)
- Hyogo Prefectural Cancer Center (JP)
- Kindai University (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Osaka City General Hospital (JP)
- Osaka Habikino Medical Center (JP)
- NHO Kinki Chuo Chest Medical Center (JP)
- Kobe City Medical Center General Hospital (JP)
- Kurashiki Central Hospital (JP)
- Kouseiren Takaoka Hospital (JP)
- Osaka City University (JP)
- Tottori University (JP)
- Okayama University (JP)
- Corresponding author
- Mitsudomi, Tetsuya
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 11
- Issue
- 2
- Pages
- 121-128
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2129360604
- Cited by
- 4,090
- References
- 34
- Citations by year
- 2026: 31 · 2025: 110 · 2024: 130 · 2023: 140 · 2022: 211 · 2021: 228 · 2020: 236 · 2019: 264 · 2018: 318 · 2017: 329 · 2016: 312 · 2015: 382 · 2014: 372 · 2013: 352 · 2012: 300
- FWCI
- 187.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Sanofi
- European Society for Medical Oncology
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- gefitinib, non-small cell lung cancer, EGFR mutation, EGFR tyrosine kinase inhibitors, exon 19 deletion, L858R mutation, progression-free survival, platinum-based chemotherapy, first-line therapy, myelosuppression, postoperative recurrence
- MeSH terms
- Docetaxel, Gefitinib, Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Quinazolines, Taxoids, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
